THERAPY DOSSIER · th-d41164fde4f2

Injury-site targeted complement inhibitors CR2-fH, CR2-Crry and CR2-CD59

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29437855 ↗2018Mixed findings

Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury.

MouseTBIControlled cortical impactC57BL/6MaleAcute administration after controlled cortical impact

Model: Controlled cortical impact traumatic brain injury

CR2-CD59 reduced acute deficits only, whereas CR2-Crry and CR2-fH improved chronic histological, cognitive and functional outcomes, indicating the alternative pathway drives chronic pathology.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…